Development of Monoclonal Antibody-based Assays for Detection and Qualification o

开发基于单克隆抗体的检测和鉴定方法

基本信息

  • 批准号:
    8379179
  • 负责人:
  • 金额:
    $ 9.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

Artemisinin-based combination therapies (ACTs) play an essenfial role in the current malaria control and elimination campaign. However, the circulation of counterfeit and substandard artemisinins greatly threatens the malaria control efforts. Fake artemisinins containing no or little acfive ingredients are life-threatening, while substandard drugs encourage resistance development. The scale of this 'lethal problem' is particulariy huge in some Southeast Asian countries, where as much as 64% of the artesunate sold on the market was fake. To prolong the life span of artemisinin drugs for treating malaria, strict drug quality control needs to be implemented in these nafions. For this purpose, fast and reliable methods of artemisinin detection and quanfitation are needed. Traditional methods for quantitation of artemisinins often require expensive instruments and substantial technical support, whereas the rapid qualitative method for screening of fake artemisinin derivatives is less sensifive and variable. Based on our recent success of developing a highly sensifive and reliable enzyme-linked immunosorbent assay (ELISA) using a specific monoclonal anfibody against artemisinins, we propose to 1) develop a series of monoclonal antibodies with specificities for the major artemisinin derivatives (dihydroartemisinin, artemether, arteether, and artesunate) using an innovative design of immunogens, 2) develop and optimize an ELISA for accurate quantification of artemisinins, and a lateral flow dipsfick assay for rapid, semi-quanfitafive analysis of artemisinins in anfimalarial drugs, 3) perform systematic field surveys of the drug quality of artemisinin-based anfimalarial medicines in three Southeast Asian countries using these new tools, and 4) optimize the ELISA conditions so that it can be used as an alternative tool for quantification of artemisinins and its derivatives in pharmacokinetic studies. These immunoassays will offer convenient tools for both accurate quanfificafion of artemisinins and rapid detecfion of counterfeit and substandard artemisinin derivative drugs, contribufing to anfimalarial drug quality control.
以青蒿素为基础的联合疗法在目前的疟疾控制中发挥着重要作用, 消除运动。然而,假冒伪劣青蒿素的流通极大地威胁着 控制疟疾的努力。不含或含有少量acfive成分的假青蒿素会危及生命, 而不合格的药物会鼓励耐药性的产生。这个“致命问题”的规模在一些东南亚国家尤其巨大,在那里,市场上销售的青蒿琥酯多达64%是假的。为延长青蒿素类抗疟药的使用寿命,需要对这些国家的青蒿素类抗疟药进行严格的质量控制。为此,需要快速可靠的青蒿素检测和定量方法。传统的青蒿素定量方法往往需要昂贵的仪器和大量的技术支持,而快速定性方法用于筛选假青蒿素衍生物的灵敏度和可变性较低。基于我们最近成功地建立了一种高灵敏度和可靠的青蒿素单克隆抗体酶联免疫吸附试验(ELISA),我们提出:1)研制一系列对主要青蒿素衍生物具有特异性的单克隆抗体(双氢青蒿素、蒿甲醚、蒿乙醚和青蒿琥酯),2)建立并优化了青蒿素的ELISA定量方法和抗疟药中青蒿素的快速半定量分析方法,3)使用这些新工具,在三个东南亚国家对青蒿素类抗疟药物的药物质量进行系统的实地调查,优化酶联免疫吸附试验条件,使其可作为青蒿素及其衍生物药代动力学研究中定量分析的替代工具。 这些免疫分析方法为青蒿素类药物的准确定量和快速检测伪、劣药提供了方便的手段,有助于抗疟药的质量控制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Baomin Wang其他文献

Baomin Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Baomin Wang', 18)}}的其他基金

Development of Monoclonal Antibody-based Assays for Detection and Qualification o
开发基于单克隆抗体的检测和鉴定方法
  • 批准号:
    8500148
  • 财政年份:
    2013
  • 资助金额:
    $ 9.82万
  • 项目类别:
Development of Monoclonal Antibody-based Assays for Detection and Qualification o
开发基于单克隆抗体的检测和鉴定方法
  • 批准号:
    8311801
  • 财政年份:
    2011
  • 资助金额:
    $ 9.82万
  • 项目类别:
Development of Monoclonal Antibody-based Assays for Detection and Qualification o
开发基于单克隆抗体的检测和鉴定方法
  • 批准号:
    8005219
  • 财政年份:
    2010
  • 资助金额:
    $ 9.82万
  • 项目类别:
Development of Monoclonal Antibody-based Assays for Detection and Qualification of Artemisinin Derivatives
开发基于单克隆抗体的青蒿素衍生物检测和鉴定方法
  • 批准号:
    9306586
  • 财政年份:
  • 资助金额:
    $ 9.82万
  • 项目类别:
Development of Monoclonal Antibody-based Assays for Detection and Qualification of Artemisinin Derivatives
开发基于单克隆抗体的青蒿素衍生物检测和鉴定方法
  • 批准号:
    8691669
  • 财政年份:
  • 资助金额:
    $ 9.82万
  • 项目类别:

相似海外基金

Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
  • 批准号:
    MR/X030202/1
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
  • 批准号:
    10742205
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
  • 批准号:
    10635649
  • 财政年份:
    2023
  • 资助金额:
    $ 9.82万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10534667
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10533634
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
  • 批准号:
    2749037
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Studentship
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
  • 批准号:
    468862
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
    Operating Grants
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10646331
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10368441
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10663334
  • 财政年份:
    2022
  • 资助金额:
    $ 9.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了